IMNM
Immunome, Inc. [IMNM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMNM Stock Summary
Top 10 Correlated ETFs
IMNM
Top 10 Correlated Stocks
IMNM
In the News
IMNM Financial details
Company Rating
-
Market Cap
879.38M
Income
-22.38M
Revenue
10.19M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
14 Mar 2024
P/E
-6.54
Forward P/E
-
PEG
4.95
P/S
50.31
P/B
24.1
P/C
-
P/FCF
193.2
Quick Ratio
3.92
Current Ratio
3.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.84
EPS next Y
-
EPS next Q
-
EPS this Y
45.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-16.37%
EPS Q/Q
-21.74%
-
-
-
-
SMA20
14.29%
SMA50
-20%
SMA100
-38.46%
Inst Own
-
Inst Trans
-
ROA
-24%
ROE
-195%
ROC
-0.32%
Gross Margin
100%
Oper. Margin
-222%
Profit Margin
-220%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.44-30.958
52W High
-70.7%
52W Low
+119.75%
RSI
62
Rel Volume
1.18
Avg Volume
747.88K
Volume
881.83K
Perf Week
7.33%
Perf Month
2.57%
Perf Quarter
-32.23%
Perf Half Y
-29.28%
-
-
-
-
Beta
1.557
-
-
Volatility
0.11%, 0.97%
Prev Close
2.93%
Price
8.79
Change
2.09%
Company Profile
- Volume Average 747.88K
- Market Capitalization 879.38M
- Employee 37
- CEO Dr. Clay B. Siegall Ph.D.
- Headquarters Exton,PA,US
- IPO Date 2020-10-02
-
Website
https://immunome.com 
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
